Business Daily from THE HINDU group of publications
Thursday, Dec 06, 2007
ePaper | Mobile/PDA Version
Business Daily from THE HINDU group of publications Thursday, Dec 06, 2007 ePaper | Mobile/PDA Version |
|
|
|
|
|
|
|
|
Home Page
-
Pharmaceuticals Corporate - Corporate Disputes Marketing - IPR
Our Bureau Mumbai, Dec. 5 Sun Pharma’s generic drugs business in the US received a shot in the arm, after Novartis dropped a patent infringement suit against it and Watson Pharmaceuticals Inc over its Alzheimers and dementia drug Exelon. “Claims against the generic-drug companies were dismissed,” said a news-agency report, citing a court document filed late last month at the federal court in New York. The development comes a little more than a month after Sun Pharma got regulatory approval from the US Food and Drug Administration to sell Rivastigmine Tartrate, the generic version of Exelon. However, it is still unclear when the company will launch the product in the US following the latest development. The Mumbai-based drug maker had got US FDA approvals to sell Rivastigmine in four different potencies and these strengths have annual sales of about $200 million in the US. Sun Pharma, being one of the first to file an abbreviated new drug application to sell generic Exelon in the US, is also eligible to share 180-day marketing exclusivity on the drug. The company’s shares closed at Rs 1,104 on Wednesday, up almost two per cent on the BSE. Dr Reddy’s Laboratories too had received US regulatory approval earlier this month to sell generic Exelon. Reports indicate that Ranbaxy also had received a tentative US FDA approval to sell the generic version of the drug. More Stories on : Pharmaceuticals | Corporate Disputes | IPR | Sun Pharmaceutical Industries Ltd
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2007, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|
